L. Sloan

发表

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

B. Ha, E. Dejesus, C. Small, 2013, BMC Infectious Diseases.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

D. Fine, Kimberly Smith, N. Bellos, 2009, AIDS.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.

J. Banchereau, A. Palucka, Y. Lévy, 2011, Journal of immunological methods.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

S. Piscitelli, T. Fujiwara, T. Hawkins, 2011, AIDS.

Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load

Rodolphe Thiébaut, Geneviève Chêne, Karolina Palucka, 2014, European journal of immunology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells

J. Banchereau, Y. Lévy, G. Zurawski, 2013, AIDS.

Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients

D. Ward, R. Ebrahimi, J. Morales-Ramirez, 2009, Journal of acquired immune deficiency syndromes.

Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study

A. Lazzarin, J. Currier, N. Clumeck, 2008, Antiviral Therapy.